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In the present habilitation thesis, I structured my scientific work into thematically different parts 
related to different mechanism of interaction of viruses with the cell. These parts are connected with 
my projects, laboratories and investigated viruses. I introduce each part by scientific and 
organizational context followed by the most representative papers. The overview of my research 
activity is shown in Table 1. 
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1973-1980 REPLICATION OF HUMAN HERPES VIRUS TYPE 1 (HHV-1) (8 PAPERS) 
 
Context 
My implication in the field of human virology started in 1973 at the Department of Experimental 
Virology of the Institute of Sera and Vaccines (ÚSOL) in Prague, under direction of Prof. Vladimir 
Vonka. As a part of a broad project on the etiological role human herpesviruses in cancer, I was 
involved in the study of molecular mechanisms of replication of Human herpesvirus type 1 (HHV-1), 
known also as Herpes simplex virus type 1 (HSV-1). I began my scientific career by demonstration of 
the presence of ribonucleotides linked to DNA of HSV-1 (Hirsch and Vonka, 1974) [37 times cited]. In 
parallel, I started to investigate molecular topology of HSV DNA, and molecular characteristics of 
newly synthesized HSV-1 DNA, exemplified by reference (Hirsch et al., 1976) [20 times cited]. I 
continued in this research direction during my postdoctoral stay at the Department of Virology and 
Epidemiology, Baylor College of Medicine in Houston, TX, under direction of Prof. Joseph L. Melnick 
(granted by the International Agency for Research on Cancer (IARC) WHO), exemplified by reference 
(Hirsch et al., 1977) [36 times cited]. 
 
Research outcome 
Our study, which demonstrated the presence of ribonucleotides linked to genomic HSV-1 DNA 
(Hirsch and Vonka, 1974) followed a long lasting discussion about the presence of single stranded 
interruptions in the double-stranded DNA of HSV-1. The interruptions could be related to repair 
replication of viral and cellular DNA in HSV-infected cells, or to the presence of ribonucleotides 
sensible to alkaline conditions in the single stranded interruption detection system (Nishiyama and 
Rapp, 1981; Roizman, 1979a). In our paper, we infected cells of a continuous cell line derived from 
rabbit embryo fibroblasts with HSV-1 and maintained in the presence of either [5-3H]uridine or 
[methyl-3H]thymidine or 32PO43-. Nucleocapsids were isolated from the cytoplasmic fraction, partially 
purified, and treated with DNase and RNase. From the pelleted nucleocapsids, DNA was extracted and 
purified by centrifugation in sucrose and cesium sulfate gradients. The acid-precipitable radioactivity 
of [5-3H]uridine-labeled DNA was partially susceptible to pancreatic RNase and alkaline treatment; 
the susceptibility to the enzyme decreased with increasing salt concentration. No drop of activity of 
DNA labeled with [3H]thymidine was observed either after RNase or alkali treatment. Base 
composition analysis of [5-3H]uridine-labeled DNA showed that the radioactivity was recovered as 
uracil and cytosine. In the cesium sulfate gradient, the purified [5-3H]uridine-labeled DNA banded at 
the same position as the 32P-labeled DNA. The presented data tended to suggest that ribonucleotide 
sequences are present in HSV DNA, that they are covalently attached to the viral DNA, and that they 
can form double-stranded structures.  
 
Together with the structure of HSV DNA, we studied also its replication (Hirsch et al., 1976). 
Conclusions of this work were consistent with isomerization of UL and US segments of HSV DNA, 
and replication of genetic material of HSV via the formation of concatemers; it preceded suggestion of 
the rolling circle mechanism of HSV DNA replication (Roizman, 1979a, b). In addition, we 
investigated formation of single-stranded interruptions during DNA replication. HSV DNA yielded a 
heterogeneous sedimentation profile in neutral sucrose gradients, with the main peak occurring at 
approximately 40S. Components sedimenting slower than virion DNA and a rapidly sedimenting 
intracellular HSV DNA were also observed. Both the low-molecular weight and the rapidly 
sedimenting components seemed to be precursors of virion DNA: they almost completely disappeared 
after a 60-min chase of a 3-min pulse of 3H-thymidine, and were converted into DNA which 
cosedimented with virion 32P-labeled DNA. However, sedimentation analysis in alkaline sucrose 
gradients showed that a 60-min period was insufficient for completing the maturation of HSV DNA. 
No evidence for the formation of covalently closed circles during the replication process was obtained. 
The presence of single-stranded regions in the replicative form of HSV DNA was revealed. Some of 
the short-pulse (30 sec) labeled HSV DNA (26.1%) was eluted from hydroxylapatite columns with the 
properties of single-stranded DNA, and 22% of its trichloroacetic acid precipitability was susceptible 
to single-strand specific S1 nuclease treatment. Pulse-chase experiments indicated that the life-time of 
this single-stranded component in nascent DNA was probably not longer than 3 min. A small 
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proportion of single-stranded regions, however, survived for longer periods. Almost all of the newly 
synthesized short-pulse-labeled HSV DNA exhibited an affinity for nitrocellulose filters. This affinity, 
which was S1 nuclease-sensitive, gradually decreased with prolongation of the time of the chase. After 
chasing the pulse for 1 h, the attachment of newly synthesized DNA was comparable with virion 
DNA.  
 
Then we analyzed intracellular replicating molecules of HSV-1 DNA by use of restriction 
endonucleases and electron microscopy (Hirsch et al., 1977) (Figure 1). HSV-1 infected rabbit kidney 
cells were either pulse-labeled with [3H]thymidine ([3H]dT) or density-labeled with 5-
bromodeoxyuridine (BUdR). Replicating [3H]dT-labeled HSV-1 DNA (CsCl = 1.725 g/cm3) or BUdR-
labeled HSV-1 DNA HSV (CsCl = 1.750 g/cm3) were isolated by CsCl density gradient centrifugation. 
Viral molecules with sedimentation coefficients of 56 to 86 S were isolated, concentrated, mixed with 
32P-labeled marker 56 S DNA from purified virions, and cleaved with EndoR.EcoRI or Hind III. The 
highest 3H to 32P ratio for replicating HSV-1 DNA was found in fragments constituting the joint region 
of HSV-1 DNA. Electron microscopic observations of replicating molecules revealed the presence of 
both internal replication loops and lariat-type molecules. Though the origin and function of the lariat 
molecules is not known, the results presented suggest that the origin of HSV-1 DNA synthesis is 
located in the joint region of the S arm of the molecule. Our study helped to elaborate the model of 
HSV DNA replication by the rolling circle mechanism (Mocarski and Roizman, 1982; Roizman, 
1979a, b). 
 
Figure 1. Electron micrographs of HSV 
DNA molecules extracted from RK cells at 3 
hr p.i. (A and B) representative molecules 
containing terminal lariat structures.  
 
The end loop (large arrow) generally does not 
exceed 5 m. A small circular molecule is 
indicated by the small arrow. The bars 






1984-1985 ETIOLOGICAL ROLE OF HSV-1 CERVICAL CARCINOMA (4 PAPERS) 
 
Context 
After my return from postdoctoral stay at the Baylor College of Medicine back to ÚSOL, I participated 
due to my experience in the field of molecular biology of HSV-1 in a consortium of experts, guided by 
Prof. Vladimír Vonka, in the prospective study on the relationship between cervical neoplasia and 
HSV-2, a major project at the Department of Experimental Virology (ÚSOL), exemplified by 
references (Vonka et al., 1984a; Vonka et al., 1984b) [71 and 85 times cited]. My major role in this 
prospective study was to develop a type specific test differentiating HSV-1 and HSV-2 antibodies 




To determine the risk associated with previous HSV-2 infection and possibly other virus infections, a 
prospective study of cervical neoplasia in more than 10,000 women was performed in the 1975-1983 
period (Vonka et al., 1984b). The subjects were selected at random from an alphabetical listing of 
eligible women living in one district of Prague. At enrollment colposcopy and cervical cytology were 
performed, a blood sample was taken and data regarding education, socio-economic status, personal 
habits and sexual and reproduction-associated attributes were obtained from each woman. A total of 
10,683 women were enrolled; a complete set of data was obtained in 10,389 women. Women with 




investigations after 2 years and 4 years, the other women were followed at 3- to 6-monthly intervals. 
In women with highly significant findings, histological investigation was performed. The total of 150 
cases of moderate to severe dysplasia (i.e. cervical intraepithelial neoplasia, grade II, CIN II), 83 cases 
of carcinoma in situ (CIN III) and 21 cases of invasive carcinoma (INCA) were detected. More than 
60% of the patients were ill at enrollment, the other cases developed in subjects with originally 
slightly suspicious (27 CIN II, 17 CIN III, 3 INCA) or negative findings (30 CIN II, 12 CIN III, 3 
INCA). Analysis of the data indicated significantly positive correlation of one or more of these clinical 
conditions with a number of sexual and reproduction-related attributes of which early age at first 
intercourse was most consistent. Among the other attributes, the smoking habit was associated with 
the highest risk of developing the disease. A negative correlation of cervical neoplasia with several 
attributes was demonstrated; of these diathermoelectrocoagulation of the ectopic epithelium and 
transformation zone of cervix was the most important single protective factor. On the basis of these 
findings, control subjects were selected for serological studies.  
 
HSV-1 and HSV-2 antibodies in individuals enrolled in the prospective study were determined by a 
micro-solid-phase radioimmunoassay with Helix pomatia lectin/Sepharose 4B-purified antigens from 
HSV-1- and HSV-2-infected cells (Suchankova et al., 1984). A low but constant heterotypic reactivity 
was found with HSV-1 antigen, whereas HSV-2 antigen was type specific, as evidenced by (1) its 
reactivity with sera from HSV-2- but not with those from HSV-1-immunized animals, (2) its reactivity 
with monoclonal antibody to glycoprotein C but not with that to other HSV-2 glycoproteins, and (3) 
the negative results obtained in serum samples from 57 children, of whom 49 possessed HSV-1 
neutralizing antibody. Antibody to HSV-2 (anti-HSV-2) was detected in serum samples from 14 of 16 
subjects treated for genital herpetic lesions. The prevalence of anti-HSV-2 in women did not differ in 
the 25-35- and 36-45-year-old age groups but did correlate with the number of sex partners, with only 
10% of women reporting one sex partner and 33% of those reporting more than 10 sex partners having 
anti-HSV-2. 
 
Sera obtained at enrollment in the study from patients suffering from moderate to sever dysplasia 
(cervical intraepithelial neoplasia grade II), carcinoma in situ (cervical intraepithelial neoplasia grade 
III) and invasive carcinoma, or developing any of these conditions in the course of the prospective 
study, and from control subjects, were examined for HSV-2 antibody presence (Vonka et al., 1984a) 
[85 times cited]. We used Helix pomatia lectin-purified antigens from HSV-1- and HSV-2-infected 
cells for this purpose (Suchankova et al., 1984). The controls were matched with the patients by age, 
age at first intercourse, number of sexual partners, smoking habits and history of 
diathermoelectrocoagulation of the ectopic epithelium and transformation zone of cervix. Only those 
subjects were selected as controls who remained free of pathological colposcopical and cytological 
findings throughout the observation period, i.e. for at least 4 years after their serum sample was 
obtained. The microneutralization test (MNT) and type-2-specific solid-phase radioimmunoassay 
(SPRIA) were used as serological tests. No difference in the prevalence of HSV-2 antibody between 
the patients and controls was revealed by either test. Various combinations of the results from the two 
tests also failed to show any difference between patients and controls. Moreover, no significant 
differences were observed in the prevalence of HSV-2 antibody between patients suffering from the 
various pathological conditions and those diagnosed at enrollment and later in the course of the study. 
These results do not provide any support for the hypothesis of the involvement of HSV-2 in cervical 
neoplasia. Our conclusions paved the way to discovery of papillomaviruses as the etiological agent of 
cervical neoplasia (zur Hausen, 2009). 
 
1978-1988 ETIOLOGICAL ROLE OF EPSTEIN-BARR VIRUS (EBV) IN 
OROPHARYNGEAL CARCINOMA (16 PAPERS) 
 
Context 
In addition to the study of the role of HSV in cervical carcinoma, we investigated at the Department of 
Experimental Virology (ÚSOL) together with my PhD student Beda Břicháček also involvement of 
EBV in oropharyngeal carcinomas based mostly on the research of EBV footprints in oropharyngeal 




In parallel to our study of the etiological role of HSV in cervical carcinoma, we investigated 
involvement EBV in oropharyngeal carcinoma. While the etiologic role of EBV in Burkitt lymphoma 
and nasopharyngeal carcinoma was clearly demonstrated, its role in other neoplasia is less clear 
(Iezzoni et al., 1995; Young et al., 1988). We focused our attention to tissues originating, like 
nasopharynx, from the Waldeyer´s ring, the palatine tonsils and the supraglottic larynx. The presence 
of EBV genetic material was demonstrated in thin sections of biopsy specimens in 6 of 7 carcinomas 
of human palatine tonsil by the in situ hybridization test (Brichacek et al., 1984) (Figure 2). The 
biopsy specimens from 4 tonsillar carcinomas exhibited a strong positive reaction; two biopsy 
specimens were weakly positive. Two tumor-free biopsy specimens were negative. None of the thin 
sections reacted with 3H-labeled HSV DNA probe. Collectively, our results suggest an association 
between EBV and tonsillar carcinoma. 
 
 
Figure 2. Autoradiogram of an in situ hybridization of 'H-Iabeled EBV DNA with thin section of the (2A) patient #1 
(bar=15 µm) and (2B, next plate) patient #2 (bar=20 µm) tonsillar tumors.  
 
The two tissues were tested in two different experiments. From (Brichacek et al., 1984). 
 
In another study, thin sections of biopsies from five patients with supraglottic laryngeal carcinoma 
who possessed antibody to early antigen of EB virus were examined for the presence of EB virus 
nuclear antigen (EBNA) and EB virus DNA by cytological hybridization in situ (Brichacek et al., 
1983). Both EBNA and EB virus DNA were found in the tumour cells of three of the patients. The 
present findings suggest an association between EB virus and supraglottic carcinoma of the larynx. 
 
1990- ACTIVE: HIV-1 LATENCY AND VIRUS RESERVOIRS (14 PAPERS) 
 
Context 
A major scientific subject of my research group established in Inserm laboratory in Marseille, France, 
directed by Jean-Claude Chermann, where I moved in 1988, was investigation of HIV-1 persistence 
and latency. Our research activity was focused to the study of establishment and eradication of virus 
reservoir(s) in patients treated by antiretroviral therapy (ART). These projects were supported by 
Inserm and by the French National Agency for AIDS research and virus hepatitis (ANRS); our results 
from this period are exemplified by references (Pion et al., 2003a) [32 times cited], (Blazkova et al., 
2009) [126 times cited], (Sanchez et al., 1997) [88 times cited], (Biancotto et al., 2004) [51 times 
cited], (Anastasi et al., 2004) [21 times cited]. In this project I have collaborated intensively with 
Leonid B. Margolis from NICHD NIH, Bethesda, MD (Biancotto et al., 2004; Biancotto et al., 2008; 
Brichacek et al., 2010; Gondois-Rey et al., 2002), with Ruth M. Ruprecht from the Dana Farber 
Cancer Institute at the Harvard Medical School (Pion et al., 2001; Pion et al., 2003b), with Eric 
Verdin from the Gladstone Institute at UCSF (Blazkova et al., 2009; Pion et al., 2003a), with Carine 
van Lint from the Université Libre de Bruxelles, Brussels (Blazkova et al., 2009) (Pierard et al., 2010) 
and with Jiri Hejnar from the Institute of Molecular Genetics in Prague (Blazkova et al., 2009; Pion et 








The current protocols of ART are efficient in decreasing the HIV-1 load below the limit of detection, 
reducing mortality due to HIV-1 infection. Despite the potency of ART, however, HIV-1 establishes 
latent infection in several cell-type reservoirs, including that consisting of resting memory CD4+ T 
cells, which escapes host immune responses and antiretroviral therapy. HIV-1 latency is thus the main 
obstacle to the eradication of the virus from infected patients (Archin et al., 2014; Eisele and Siliciano, 
2012; Ho et al., 2013; International et al., 2012; Palmer et al., 2011; Trono et al., 2010; Virgin and 
Walker, 2010).  
 
DNA methylation of retroviral promoters and enhancers localized in the provirus 5' long terminal 
repeat (LTR) is considered to be a mechanism of transcriptional suppression that allows retroviruses to 
evade host immune responses and antiretroviral drugs. However, the role of DNA methylation in the 
control of HIV-1 latency has never been unambiguously demonstrated, in contrast to the apparent 
importance of transcriptional interference and chromatin structure, and has never been studied in HIV-
1-infected patients. In contrast to the previously described systems, we and others have shown that 
transcriptional suppression of wild-type HIV-1 promoter is not accompanied by CpG methylation of 
the 5´ LTR (Blazkova et al., 2009; Duverger et al., 2009; Pion et al., 2003a). 
 
In our first study on HIV-1 persistency we demonstrated that transcriptional suppression of in vitro-
integrated HIV-1 does not correlate with proviral DNA methylation (Pion et al., 2003a). We 
investigated whether the CpG methylation of the HIV-1 promoter can directly influence the expression 
of the HIV-1 genome and thereby contribute to the persistence and latency of HIV-1. The levels of 
CpG methylation in the promoter of HIV-1 were studied after bisulfite-induced modification of DNA 
in five Jurkat clonal cell lines transduced by an HIV-1 LTR-driven retroviral vector and expressing 
enhanced green fluorescent protein (GFP) and in primary resting memory T cells challenged with 
HIV-1 or with an HIV-1-derived retroviral vector. We found that basal HIV-1 promoter activities were 
low or undetectable in three tested HIV-1 LTR-GFP clones, one of which encoded the Tat protein, and 
they reached medium or high levels in two other clones. The CpG dinucleotide that occurred in a 
latently infected clonal cell line 240 nucleotides upstream of the transcription start remained 
methylated after reactivation of HIV-1 transcription with 10 nM phorbol-12-myristate-13-acetate. In 
two clones showing a medium promoter activity and in resting memory T cells, the HIV-1 LTR was 
generally not methylated. Our results show that the methylation profiles of the HIV-1 LTR, including 
those present in latently infected cells, are low and do not correlate with the transcriptional activity. 
We suggest that, in a noncloned cellular population in which the HIV-1 proviruses are randomly 
integrated in the human genome, HIV-1 latency is imperfectly controlled by CpG methylation and is 
inherently accompanied by residual replication.  
 
In our second study on persistent infection with HIV-1, we showed in an in vitro model of reactivable 
latency and in a latent reservoir of HIV-1-infected patients that CpG methylation of the HIV-1 5' LTR 
is an additional epigenetic restriction mechanism, which controls resistance of latent HIV-1 to 
reactivation signals and thus determines the stability of the HIV-1 latency (Blazkova et al., 2009). 
CpG methylation acts as a late event during establishment of HIV-1 latency and is not required for the 
initial provirus silencing (Figure 3). Indeed, the latent reservoir of some aviremic patients contained 
high proportions of the non-methylated 5' LTR. The latency controlled solely by transcriptional 
interference and by chromatin-dependent mechanisms in the absence of significant promoter DNA 
methylation tends to be leaky and easily reactivable. In the latent reservoir of HIV-1-infected 
individuals without detectable plasma viremia, we found HIV-1 promoters and enhancers to be 
hypermethylated and resistant to reactivation, as opposed to the hypomethylated 5' LTR in viremic 
patients. However, even dense methylation of the HIV-1 5' LTR did not confer complete resistance to 
reactivation of latent HIV-1 with some histone deacetylase inhibitors, protein kinase C agonists, TNF-
alpha, and their combinations with 5-aza-2deoxycytidine: the densely methylated HIV-1 promoter was 
most efficiently reactivated in virtual absence of T cell activation by suberoylanilide hydroxamic acid 
(SAHA). SAHA could be a part of the “kick and kill” strategy, in which latent proviruses are first 
reactivated and then killed by efficient ART. Tight but incomplete control of HIV-1 latency by CpG 
methylation might have important implications for strategies aimed at eradicating HIV-1 infection. 
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Figure 3. Two-step model of epigenetic control of HIV-1 latency. 
  
In the state of reactivable latency exemplified by the H12 cell line, the HIV-1 promoter is hypomethylated, histone 3 (H3) is 
methylated on lysine 4 (MeK4), but deacetylated by histone deacetylases (HDAC), nuc-0 and nuc-1 are in proximal position; 
chromatin is condensed. After reactivation with TNF-α and PMA, the hypomethylated HIV-1 promoter-associated H3 is 
acetylated by means of histone acetyltransferases (HAT). Nucleosomes nuc-0 and nuc-1 are in distal position. In the “locked” 
silent state exemplified by the 2D12 cell line, the HIV-1 promoter is methylated by DNMT, and H3 is demethylated on K4 
and methylated on K9 (MeK9) and K27 (MeK27). After reactivation of the hypermethylated HIV-1 promoter the HIV-1 
LTR-associated H3 remains methylated on K27 but is demethylated on K9; CpG methylation is not changed and the 
repression is overcome by excess of transcription factors. The percentage of cells harboring reactivated HIV-1 is markedly 
lower in the clone with the “locked” highly methylated promoter (2D12) than in the clone with hypomethylated promoter 
(H12). Open circles, nonmethylated CpG residues; closed circles, methylated CpG residues, TFs, transcription factors. From 
(Blazkova et al., 2009) 
 
In addition to reactivable latency, we aimed to assess the extent of non-inducible defective HIV-1 
proviruses in infected individuals. HIV-1 genomes present in peripheral blood mononuclear cells 
(PBMCs) of infected persons or in lymphocytes infected in vitro were studied by long-distance PCR 
(LD-PCR) using primers localized in the HIV-1 LTR (Sanchez et al., 1997). The full-length 9-kb 
DNA was the only LD-PCR product obtained in peripheral and cord blood lymphocytes from 
seronegative donors infected in vitro. However, a high proportion (27% to 66%) of distinct 
populations of extensively deleted HIV-1 genomes of variable size was detected in PBMCs of 15 of 
16 HIV-1-infected persons. Physical mapping of defective genomes showed that the frequency of 
deletions is proportional to their proximity to the central part of HIV-1 genome, which is consistent 
with a deletion mechanism involving a single polymerase jump during reverse transcription. 
Sequencing of deletion junctions revealed the presence of short direct repeats of three or four 
nucleotides. The number of defective HIV-1 genomes decreased after in vitro activation of PBMCs. 
Persistence of full-length and deleted genomes in in vitro activated PBMCs correlated with isolation 
of an infectious virus. Our results represent the first quantitative assessment of intragenomic 
rearrangements in HIV-1 genomes in PBMCs of infected persons and demonstrate that, in contrast to 
in vitro infection, defective genomes accumulate in PBMCs of infected persons. 
 
Finally, to design strategies to purge latent reservoirs of HIV-1, we investigated mechanisms by which 
a non-tumor-promoting phorbol ester, prostratin, inhibits infection of CD4+ T lymphocytes and at the 
same time reactivates virus from latency (Biancotto et al., 2004). Our goal was to achieve efficient 
reactivation of HIV-1 from the latency without undesirable activation and proliferation of the immune 
system. Prostratin was a candidate agent for the “kick and kill” strategy to eradicate HIV-1 reactivated 
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from latency by efficient ART. CD4+ T lymphocytes from PBMC and in blocks of human lymphoid 
tissue were stimulated with prostratin and infected with HIV-1 to investigate the effects of prostratin 
on cellular susceptibility to the virus. The capacity of prostratin to reactivate HIV from latency was 
tested in CD4+ T cells harboring preintegrated and integrated latent provirus. Prostratin stimulated 
CD4+ T cells in an aberrant way. It induced expression of the activation markers CD25 and CD69 but 
inhibited cell cycling. HIV-1 uptake was reduced in prostratin-stimulated CD4+ T PBMC and tissues 
in a manner consistent with a downregulation of CD4 and CXCR4 receptors in these systems. At the 
postentry level, prostratin inhibited completion of reverse transcription of the viral genome in 
lymphoid tissue. However, prostratin facilitated integration of the reverse-transcribed HIV-1 genome 
in nondividing CD4+ T cells and facilitated expression of already integrated HIV-1, including latent 
forms. Thus, while stimulation with prostratin restricts susceptibility of primary resting CD4+ T cells 
to HIV infection at the virus cell-entry level and at the reverse transcription level, it efficiently 
reactivates HIV-1 from pre- and postintegration latency in resting CD4+ T cells.  
 
In addition to our effort to develop a “kick-and-kill” strategy to purge HIV-1 reservoir, I participated 
also in development of directly-acting anti-HIV-1 drugs. In collaboration with Jean-Louis Kraus from 
the Faculty of Science, Aix-Marseille University, we elaborated a concept of potent nonclassical 
nucleoside antiviral drugs based on the N,N-diarylformamidine. New formamidine-3TC (3TC = 2',3'-
dideoxy-3'-thiacytidine) analogues have been synthesized through various methods, and their antiviral 
activities (HIV, HBV) have been evaluated in vitro (Anastasi et al., 2004) [20 times cited]. Anti-HIV-
1 in acutely infected MT-4 cells and PBMCs showed that compounds substituted by N,N-
diarylformamidine side chains at the 4-N nucleic base position (compounds 3 and 8-11) had at least 
equivalent anti-HIV activity as 3TC (EC50 = 0.5 and 11.6 microM, respectively). Moreover, the newly 
synthesized compounds demonstrated higher anti-HBV activity (EC50 ranging from 0.01 to 0.05 
microM) compared to the parent nucleoside 3TC (EC50 = 0.2 microM). It should be underlined that 
these new promising derivatives inhibited HIV in cells of a macrophage lineage, which are known to 
be cellular reservoir for HIV. These results were particularly of interest, since the antiviral activities 
appeared not to be mediated through the formamidine bond hydrolysis and consequently the release of 
free 3TC. These new analogue series were found to be highly stable to hydrolysis even after prolonged 
incubation in different biological media (t(1/2) ranged from 48 to 120 h). This enzymatic stability, 
coupled to the fact that no delay in the antiviral response was observed compared to the free 3TC 
antiviral response, suggest that this new N,N-diarylformamidine nucleoside series should not be 
considered as classical prodrugs.  
 
To complement our studies on reactivation of latent replication competent HIV-1, I studied in 
collaboration with the laboratory of Jiří Hejnar from the Institute of Molecular Genetics of the 
Academy of Sciences of Czech Republic epigenetic regulation of transcription and splicing of 
syncytins, fusogenic glycoproteins of endogenous retroviral origin (Trejbalova et al., 2011). Syncytin-
1 and -2, human fusogenic glycoproteins encoded by the env genes of the endogenous retroviral loci 
ERVWE1 and ERVFRDE1, respectively, contribute to the differentiation of multinucleated 
syncytiotrophoblast in chorionic villi. In non-trophoblastic cells, however, the expression of syncytins 
has to be suppressed to avoid potential pathogenic effects. We studied the epigenetic suppression of 
ERVWE1 and ERVFRDE1 5'-LTR by DNA methylation and chromatin modifications. 
Immunoprecipitation of the provirus-associated chromatin revealed the H3K9 trimethylation at 
transcriptionally inactivated syncytins in HeLa cells. qRT-PCR analysis of non-spliced ERVWE1 and 
ERVFRDE1 mRNAs and respective env mRNAs detected efficient splicing of endogenously 
expressed RNAs in trophoblastic but not in non-placental cells. Pointing to the pathogenic potential of 
aberrantly expressed syncytin-1, we have found deregulation of transcription and splicing of the 
ERVWE1 in biopsies of testicular seminomas. Finally, ectopic expression experiments suggest the 
importance of proper chromatin context for the ERVWE1 splicing. Our results thus demonstrate that 







1990- 2013 HIV-1 PATHOGENESIS AND TROPISM (33 PAPERS) 
 
Context 
The second major HIV-1 research program of our group in the Inserm U322 laboratory in Marseille 
was the study of viral pathogenesis and tropism. As a part of this project, we characterized HIV-1 
isolates obtained in the Pasteur institute early after the virus isolation in 1983 (Chermann et al., 
1991). We showed that the initial HIV-1 (BRU) isolate, growing strictly in primary T cells, was 
contaminated during the summer 1983 by HIV-1 (LAI) isolate, able to grow in T cell lines. 
Contaminated culture was unconsciously provided to NIH, where the HIV-1 LAI was probably 
selected in the effort to isolate T cell line-adapted virus by complementation. Identification of these 
isolates was in the center of international debate on priority of HIV-1 discovery between Luc 
Montagnier and Robert Gallo. Our work on pathogenesis project continued when my group moved to 
the Marseille Centre for Cancer Research (CRCM) of INSERM, affiliated also to the Aix-Marseille 
University and to the IPC Cancer Research Hospital. We developed a model system based on the 
construction of recombinants between highly cytopathic Zairian strain HIV-1 NDK and a prototype 
HIV-1 virus (Hirsch et al., 1990)[33 times cited], (Rey et al., 1991) [72 times cited], and studied HIV-
1 tropism in trophoblasts (Zachar et al., 1991) [62 times cited], macrophages (Schmidtmayerova et 
al., 1992) [45 times cited], and intestinal cells (Chenine et al., 2002). 
 
Research outcome 
We showed that HIV-1 uses flexible replication strategies to infect different cell types and adapts 
efficiently in a new host cell. Our major model system consisted of a highly cytopathic subtype D 
Zairian strain HIV-1 NDK and recombinants derived from this and a prototype strain. We 
demonstrated that typically lymphotrpic HIV-1 NDK is able to infect in addition to primary CD4+ T 
lymphocytes and CD4+ T cell lines, also macrophages, trophoblasts and intestinal cells by CD4-
independent mechanism. 
 
In the first report of this series we howed that differences in replication and cytopathogenicity of HIV-
1 are not determined by LTR. The growth properties of molecular clones of a highly cytopathic 
Zairian HIV1-NDK and prototype viruses were compared to correlate genetic variations with 
biological changes (Hirsch et al., 1990). The cloned HIV1-NDK retained the highly replicating 
cytopathic phenotype and formed larger syncytia than the prototype. One of the major differences in 
the alignment of the nucleotide sequence of the HIV1-NDK and HIV1-BRU prototypes was localized 
in the negative regulatory element (NRE) of the long terminal repeat (LTR). In a chloramphenicol 
acetyl transferase (CAT) assay, we failed to detect a significant difference between LTR promoter 
activity of the prototype and HIV1-NDK, suggesting that the LTR of both phenotypes had a similar 
function. The complete recombinant provirus DNA molecules bearing HIV1 LTR derived from one 
phenotype and the rest of the genomes from the other phenotype were constructed and transfected. The 
high cytopathogenicity of both the original and the chimeric viruses was correlated with the high 
speed of virus replication. Cytopathogenicity, morphology of syncytia, and replication kinetics of the 
recombinant viruses were determined by the functions coded within an internal part of HIV1 genome, 
covering the gag to env region, which were, however, not within LTR.   
 
First, we demonstrated that productive infection of CD4+ cells by selected HIV strains is not inhibited 
by anti-CD4 monoclonal antibodies. Differential susceptibility of four diverse HIV strains to 
inhibition of infection of CD4+ CEM cells by anti-CD4 monoclonal antibodies was studied (Rey et al., 
1991). The highly cytopathic HIV-1 246 and NDK strains were able to infect CEM cells and undergo 
several cycles of replication at saturating doses of LEU3-A, OKT4-A, and 13B8-2 monoclonal 
antibodies, whereas propagation of reference HIV-1 BRU and weakly cytopathic strain HIV-1 PAS 
was inhibited. Postadsorption treatment by anti-CD4 antibodies had stronger inhibitory effect than did 
treatment during the virus adsorption period. In parallel experiments, the same monoclonal antibodies 
successfully blocked syncytium formation between uninfected MT4 cells and CEM cells infected by 
all four HIV-1 virus strains tested. To explain these seemingly contradictory data we have postulated 




By the same approach we demonstrated that human transformed trophoblast-derived cells lacking 
CD4 receptor exhibit restricted permissiveness for HIV-1. We investigated the nature of interaction of 
the malignantly transformed cell lines of trophoblast origin BeWo, JAR, and JEG-3 with three 
different human immunodeficiency virus type 1 (HIV-1) isolates (RF, 3B, and NDK) (Zachar et al., 
1991). After inoculation with cell-free virus, the persistence of infection was determined for 1 month 
by monitoring the presence of viral DNA in the cells by the PCR. Furthermore, the infectious virus in 
the culture supernatant was assayed with CEM-SS cells, and attempts to rescue the virus by 
cocultivation with CEM-SS cells were made. Appraised on the basis of the relative amount of viral 
DNA and the frequency of positive cocultivation. JEG-3 was the most permissive and BeWo was the 
least permissive cell line. However, when the cells were transfected with two biologically active 
molecular clones of HIV-1, the BRU and NDK isolates, all three cell lines turned out to support the 
production of mature virus progeny to the same extent. The abundance of viral DNA sequences in the 
infected cells varied with the isolate, showing an overall decline from RF to NDK. The amount of 
viral DNA in the cells and its expression decreased during the period of observation; this decrease was 
mirrored in an erosion of the virus recovery rate at cocultivation from 71% recovery on day 8 to 
failure of isolation on day 32. None of the cell lines expressed detectable amounts of cell surface CD4 
molecules when assayed by flow microfluorometry and direct radioimmunoassay. Northern (RNA) 
blot hybridization analysis of both the total RNA and the mRNA did not reveal any CD4-specific 
message: nonetheless, by using the PCR, sequences specifically related to the CD4 gene were 
uncovered. The data demonstrate that the trophoblast-derived cell lines are susceptible to infection 
with HIV and that they support transient viral replication in the initial phases of infection. However, 
the latent form of infection may persist over a period of several weeks. 
 
Then we described distinctive pattern of infection and replication of HIV-1 strains in blood-derived 
macrophages (BDM) (Schmidtmayerova et al., 1992). The macrophage-tropic virus HIV1-PAR, 
isolated from cerebrospinal fluid of HIV1-seropositive man, induced cytopathic effect accompanied by 
different magnitude of the virus production in BDM obtained from different donors. HIV1-PAR-
specific RNA was detected by in situ hybridization in 15 and 66% of BDM producing low and high 
levels of virus, respectively. In contrast with HIV1-PAR, infection of BDM with two laboratory 
strains adapted to T-cell lines, HIV1-LAV prototype and HIV1-NDK, a Zairian virus that is highly 
cytopathic for T-lymphocytes, resulted in a low production of HIV1 p24gag in culture fluid. 
Expression of HIV1-LAV and HIV1-NDK RNA was detected by in situ hybridization in a maximum 
of 1% of macrophages. Only HIV1-NDK, and not HIV1-LAV, induced ultrastructural alterations in 
BDM. In contrast with a striking difference in the production of macrophage-tropic and T-
lymphotropic viruses, no significant differences were found in the proportion of macrophages 
containing retrotranscribed genomes of HIV1-. HIV1 DNA was detected by in situ hybridization in 
93, 100, and 80% of macrophages infected with HIV1-PAR, HIV1-LAV, and HIV1-NDK, 
respectively. A higher level of HIV1 DNA was detected by PCR in the BDM infected with HIV1-PAR 
than in that infected with HIV1-LAV and HIV1-NDK. The results indicate that both macrophage-
tropic as well as T-lymphotropic viruses can enter and retrotranscribe their genomes in a vast majority 
of macrophages. 
 
2006-ACTIVE: VIRUS RESTRICTION – INTERACTION WITH THE INNATE AND 
ADAPTIVE IMMUNITY (6 PAPERS) 
 
Context 
After relocation to Marseille´s Centre for Cancer Research (CRCM, INSERM U1068) I recentered my 
interest to the study of mechanisms of chronic virus infections related to cancer. I was mostly 
interested in interaction of viruses with cellular restriction mechanisms and with natural or innate 
anti-viral immunity. Among professional immune cells responsible for anti-viral defense, we selected 
as a major subject of our scientific interest the plasmacytoid dendritic cells (pDCs), which were 
intensively investigated at CRCM also because of their involvement in non-viral cancer pathogenesis 
(overviewed in (Hirsch et al., 2010) [47 times cited]. In a project supported by ANRS we investigated 
interaction of pDCs with hepatitits C virus, as exemplified by references (Gondois-Rey et al., 2009) 




Together with my major collaborator in the “pDC-HCV  project”, Prof. Thomas Baumert from the 
Institute of virology in Strasbourg (Dental et al., 2012; Florentin et al., 2012; Gondois-Rey et al., 
2009), we studied cell signaling in hepatocytes infected by HCV ((Zona et al., 2013) [26 times cited]). 
In collaboration, with Andrea De Maria from the National Institute for Cancer Research in Genova, 
Italy, we studied effect of HCV infection on capacity of NK cells to mediate virus clearance and 
sustained immune response (Bozzano et al., 2011) [30 times cited].  
 
Our group participated in studies of the immune responses against other viruses than HCV involved in 
persistent infections. Earlier, in collaboration with Marie Suzan, we studied cell signaling triggered in 
monocytes/macrophages by HIV-1 infection (Suzan et al., 1991) [45 times cited], and more recently, 
in collaboration with Leonid B. Margolis, we studied the mechanism by which HIV-1 facilitates its 
own infection in T lymphocytes (Biancotto et al., 2008) [30 times cited]. Finally, in collaboration with 
René A. W. van Lier from the Academic Medical Center, Amsterdam, The Netherlands, we studied 
adaptive responses during primary CMV infection (Serriari et al., 2010) [31 times cited]. My present 




Viruses are recognized by pDCs through Toll-like receptors 7 and 9 (TLR7/9) localized to the 
endosomal compartment. A common functional feature of these nucleoside-sensing TLRs is the 
induction of type I interferon (IFN) and pro-inflammatory cytokines, and the induction of cell 




FIGURE 4. Control of TLR9 signaling in immature and TLR7 and TLR9 agonist-activated pDCs.  
 
(a) Immature pDCs express TLR7 and TLR9, which are constitutively expressed and reside predominantly in the ER in 
association with UNC93B, gp96 and PRAT4A. pDC-surface receptors: DCIR, which contains an ITIM (in blue); BDCA2; 
ILT7; FcɛRIα; and NKp44 associated with the γ-chain of FcɛRI (in orange) or with DAP12 (in green), both of which contain 
an ITAM (in red). (b) Following exposure to virus or to synthetic agonists, TLR7 and TLR9 relocate from the ER to the 
endosomes. After relocation into the endolysosomal compartment, TLR7 and TLR9 are cleaved by lysosomal proteases. 
Conformational changes in the TLRs lead to the activation of MyD88 and to the propagation of downstream signals, which 
result in the activation of MAPKs, NF-κB and IRF7, which leads to secretion of type I IFNs. Translocation of NF-κB to the 
nucleus upregulates TLR7, pro-inflammatory cytokines, IL-6, TNF-α, and co-stimulatory molecules CD80 and CD86, but 
downregulates expression of TLR9. From (Hirsch et al., 2010). 
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variety of cell types, these TLRs are most commonly known as strong promoters of type I IFN 
secretion from pDCs. In addition to nucleotide-sensing TLRs, pDCs also recognize pathogens through 
a battery of cell surface-localized regulatory receptors, including C-type lectin and Fc receptors. The 
principal function of these regulatory receptors on pDCs is to facilitate antigen capture and to prevent 
aberrant immune responses by modulating production of type I IFNs and pro-inflammatory cytokines. 
 
HIV-1, hepatitis B virus (HBV), hepatitis C virus (HCV), and human papillomavirus type 16 cause 
persistent infections that frequently precede cancer development (Hirsch et al., 2010). Virions of these 
viruses are weak inducers of interferon- and impair TLR9 function. Loss of TLR9 responsiveness 
also occurs in tumors without viral etiology such as breast, ovary, and head and neck carcinomas. The 
principal question was, whether these viruses and cancer cells are invisible for pDCs (stealth viruses), 
or whether these viruses and cancer cells actively inhibit immune response. Recent reports have 
suggested that viruses and components of the tumor microenviroment interact with regulatory 
receptors on pDCs to impair TLR7 and TLR9 signaling, and to downregulate TLR9 gene expression. 
Thus, impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer. The 
limited responsiveness of pDCs might contribute to reduced innate immune responses during chronic 
viral infections and oncogenesis, and represent a target for new therapeutic approaches based on TLR 
agonists. 
 
We used HCV and its interaction with pDC as a major model in our studies. Viral elimination by IFN-
-based therapy in more than 50% of patients chronically infected with HCV suggests a possible 
impairment of production of endogenous IFN- by pDCs in infected individuals (Figure 4). In this 
study, we investigated the impact of HCV on pDC function. We show that exposure of pDCs to 
patient serum- and cell culture-derived HCV resulted in production of IFN- by pDCs isolated from 
some donors, although this production was significantly lower than that induced by influenza and 
HHV-1 (Gondois-Rey et al., 2009). Using specific inhibitors we demonstrate that endocytosis and 
endosomal acidification were required for IFN- production by pDCs in response to cell culture-
derived HCV. HCV and noninfectious HCV-like particles inhibited pDC-associated production of 
IFN- stimulated with TLR9 agonists (CpG-A or HHV-1) but not that of IFN- stimulated with TLR7 
agonists (resiquimod or influenza virus). The blockade of TLR9-mediated production of IFN-, 
effective only when pDCs were exposed to virus prior to or shortly after CpG-A stimulation, was 
already detectable at the IFN- transcription level 2 h after stimulation with CpG-A and correlated 
with down-regulation of the transcription factor IRF7 expression and of TLR9 expression. In 
conclusion, rapidly and early occurring particle–host cell protein interaction during particle 
internalization and endocytosis followed by blockade of TLR9 function could result in less efficient 
sensing of HCV RNA by TLR7, with impaired production of IFN-. This finding confirmed also by 
work from other laboratories (Decalf et al., 2007; Shiina and Rehermann, 2008) is important for our 
understanding of HCV-DC interaction and immunopathogenesis of HCV infection. 
 
Then we studied differences in recognition of cell-free HCV particles and cell-associated HCV (HCV-
infected hepatoma cells) by pDCs. pDCs exposed to HCV-infected hepatoma cells, in contrast to cell-
free HCV virions, produce large amounts of IFN-α. To further investigate the molecular mechanism of 
HCV sensing, we studied whether exposure of pDCs to HCV-infected hepatoma cells activates, in 
parallel to interferon regulatory factor 7 (IRF7)-mediated production of IFN-α, nuclear factor kappa B 
(NF-κB)-dependent pDC responses, such as expression of the differentiation markers CD40, CCR7, 
CD86, and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and secretion of 
the proinflammatory cytokines TNF-α and interleukin 6 (IL-6) (Dental et al., 2012). We demonstrate 
that exposure of pDCs to HCV-infected hepatoma cells surprisingly did not induce phosphorylation of 
NF-κB or cell surface expression of CD40, CCR7, CD86, or TRAIL or secretion of TNF-α and IL-6. 
In contrast, CpG-A and CpG-B induced production of TNF-α and IL-6 in pDCs exposed to the HCV-
infected hepatoma cells, showing that cell-associated virus did not actively inhibit TLR-mediated NF-
κB phosphorylation. Our results suggest that cell-associated HCV signals in pDCs via an endocytosis-
dependent mechanism and IRF7 but not via the NF-κB pathway. In spite of IFN-α induction, cell-
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associated HCV does not induce a full functional response of pDCs. These findings contribute to the 




In our most original report of this series, we showed that HCV glycoprotein E2 is a novel BDCA-2 
ligand and acts as an inhibitor of IFN production by pDCs, similarly as was shown for HIV-1 gp120 
(Martinelli et al., 2007) (Figure 5). The elimination of HCV in > 50% of chronically infected patients 
by treatment with IFN- suggests that pDCs, major producers of IFN-, play an important role in the 
control of HCV infection. However, despite large amounts of Toll-like receptor 7-mediated IFN-, 
produced by pDCs exposed to HCV-infected hepatocytes, HCV still replicates in infected liver. We 
showed that HCV envelope glycoprotein E2 is a novel ligand of pDC C-type lectin immunoreceptors 
(CLRs), blood DC antigen 2 (BDCA-2) and DC-immunoreceptor (DCIR) (Florentin et al., 2012). 
HCV particles inhibit, via binding of E2glycoprotein to CLRs, production of IFN- and IFN- in 
pDCs exposed to HCV-infected hepatocytes (Dolganiuc and Szabo, 2011; Takahashi et al., 2010), and 
induce in pDCs a rapid phosphorylation of Akt and Erk1/2, in a manner similar to the crosslinking of 
BDCA-2 or DCIR. Blocking of BDCA-2 and DCIR with Fab fragments of monoclonal antibodies 
preserves the capacity of pDCs to produce type I and III IFNs in the presence of HCV particles. Thus, 
negative interference of CLR signaling triggered by cell-free HCV particles with Toll-like receptor 
signaling triggered by cell-associated HCV results in the inhibition of the principal pDC function, 
production of IFN. Our results demonstrate that exposure of pDCs to cell-free or cell-associated form 
of the same virus results in a totally different outcome – activation or suppression of the principal pDC 
function, IFN production. These disparate effects are controlled by interaction of both viral forms with 
different types of pDC receptors and illustrate the multitude of mechanisms employed by HCV to 
escape from immune recognition (Decalf et al., 2007; Dental et al., 2012; Dolganiuc and Szabo, 2011; 
Florentin et al., 2012; Shiina and Rehermann, 2008; Takahashi et al., 2010). 
 
In collaboration with group of Thomas Baumert we studied also signal events accompanying entry of 
HCV in hepatocytes. We showed that HRas signal transduction promotes HCV cell entry by triggering 
assembly of the host tetraspanin receptor complex. It is known that HCV entry is dependent on 
coreceptor complex formation between the tetraspanin superfamily member CD81 and the tight 
junction protein claudin-1 (CLDN1) on the host cell membrane. The receptor tyrosine kinase EGFR 
acts as a cofactor for HCV entry by promoting CD81-CLDN1 complex formation via unknown 
mechanisms (Figure 6). We identify the GTPase HRas, activated downstream of EGFR signaling, as a 
FIGURE 5. Impaired TLR7 and TLR9 
signaling in virus-exposed pDCs and in tumor-
environment-exposed pDCs.  
 
The interactions that lead to impairments of TLR7 
and TLR9 signaling for HIV-1, HPV-16 and BST-
2 are illustrated as examples: HIV-1 gp120 
associates with DCIR-ITIM and BDCA2-ITAM. 
Ligation of pDC BDCA2-ITAM-associated 
regulatory receptors with HIV-1 gp120 activates 
the BCR-like NF-κB pathway, including SYK, 
BLNK, and BCAP. Ligation of pDC DCIR-ITIM-
associated regulatory receptors with HIV-1 gp120 
inhibits activation of TLR9 with its agonists. 
Engagement of the receptor by the virus can 
induce blockade of TLR9 signaling just as ligation 
of the same surface receptor with MAbs does. 
Expression of HPV-16 proteins E6 and E7 in 
keratinocytes induces NF-κB, which after 
translocation into the nucleus downmodulates 
TLR9 expression. A high concentration of ligands 
such as BST2 within a tumor tissue can be 
responsible for a reduced capacity of tumor-
associated pDCs to produce IFN-α after 
stimulation with CpG. From (Hirsch et al., 2010). 
25 
 
key host signal transducer for EGFR-mediated HCV entry (Zona et al., 2013). Proteomic analysis 
revealed that HRas associates with tetraspanin CD81, CLDN1, and the previously unrecognized HCV 
entry cofactors integrin b1 and Ras-related protein Rap2B in hepatocyte membranes. HRas signaling 
is required for lateral membrane diffusion of CD81, which enables tetraspanin receptor complex 
assembly. HRas was also found to be relevant for entry of other viruses, including influenza. Our data 
demonstrate that viruses exploit HRas signaling for cellular entry by compartmentalization of entry 
factors and receptor trafficking. 
 
 
Figure 6. EGFR Signaling Pathways in Human HCV-
Permissive Liver Cells, Hepatocytes, and Patient-Derived 
Liver Tissue 
 
Scheme of the two main canonical EGFR signaling 
cascades: the MAPK and the PI3K/AKT pathways. 
Inhibitors targeting members of these pathways are 






Efficient NK cell-anti-HCV response is essential for the virus clearance and sustained immune 
response. Specific NK cell killer inhibitory receptor (KIR):HLA haplotype combinations have been 
associated with successful clearance of acute and chronic HCV infection. Whether an imbalance of 
activating NK cell receptors also contributes to the outcome of treatment of chronic HCV infection, 
however, is not known. In collaboration with Andrea De Maria, we studied peripheral NK cell 
phenotype and function in 28 chronically viraemic HCV genotype I treatment-naıve patients who 
underwent treatment with pegylated IFN- and ribavirin (Bozzano et al., 2011). At baseline, 
chronically infected patients with sustained virological response (SVR) had reduced 
CD56brightCD16(+/-) cell populations, increased CD56dullCD161 NK cell proportions, and lower 
expression of NKp30, DNAM-1, and CD85j. Similarly, reduced NK cell IFN- production but 
increased degranulation was observed among nonresponding (NR) patients. After treatment, 
CD56brightCD16(+/-) NK cell numbers increased in both SVR and NR patients, with a parallel 
significant increase in activating NKp30 molecule densities in SVR patients only. In vitro experiments 
using purified NK cells in the presence of rIL-2 and IFN- confirmed upregulation of NKp30 and also 
of NKp46 and DNAM-1 in patients with subsequent SVR. Thus, differences in patient NK cell 
receptor expression and modulation during chronic HCV-1 infection are associated with subsequent 
outcome of standard treatment. Individual activating receptor expression/function (NKp30, NKp46, 
DNAM-1) integrates with KIR:HLA genotype carriage to determine the clearance of HCV infection 
upon combined IFN- and ribavirin treatment. 
 
Then we showed that NF-B is induced during monocyte differentiation by HIV type 1 infection. The 
production of HIV-1 progeny was followed in the U937 promonocytic cell line after stimulation, 
either with retinoic acid or PMA, and in purified human monocytes and macrophages (Suzan et al., 
1991). Electrophoretic mobility shift assays and Southwestern blotting experiments were used to 
detect the binding of cellular transactivation factor NF-B to the double repeat-B enhancer sequence 
located in the long terminal repeat. PMA treatment, and not retinoic acid treatment of the U937 cells 
acts in inducing NF-B expression in the nuclei. In nuclear extracts from monocytes or macrophages, 
induction of NF-B occurred only if the cells were previously infected with HIV-1. When U937 cells 
were infected with HIV-1, no induction of NF-B factor was detected, whereas high level of progeny 
virions was produced, suggesting that this factor was not required for viral replication. These results 
indicate that in monocytic cell lineage, HIV-1 could mimic some differentiation/activation stimuli 




macrophages is directly involved in the initiation of inflammatory reaction, a hallmark HIV-1 
infection.  
 
Furthermore, we demonstrate mechanisms by which HIV-1 appears to facilitate its own infection in ex 
vivo-infected human lymphoid tissue. In this system, HIV-1 readily infects various CD4+ T cells, but 
productive viral infection was supported predominantly by activated T cells expressing either CD25 or 
HLA-DR or both (CD25/HLA-DR) but not other activation markers: There was a strong positive 
correlation (r=0.64, P=.001) between virus production and the number of CD25+/HLA-DR+ T cells. 
HIV-1 infection of lymphoid tissue was associated with activation of both HIV-1-infected and 
uninfected (bystanders) (Biancotto et al., 2008) T cells. In these tissues, apoptosis was selectively 
increased in T cells expressing CD25/HLA-DR and p24gag but not in cells expressing either of these 
markers alone. In the course of HIV-1 infection, there was a significant increase in the number of 
activated (CD25+/HLA-DR+) T cells both infected and uninfected (bystander). By inducing T cells to 
express particular markers of activation that create new targets for infection, HIV-1 generates in ex 
vivo lymphoid tissues a vicious destructive circle of activation and infection. In vivo, such self-
perpetuating cycle could contribute to HIV-1 disease. 
 
Finally we studied the role of immune checkpoint molecules during primary human CMV infections. 
B and T lymphocyte attenuator (BTLA), like its relative programmed cell death-1 (PD-1), is a receptor 
that negatively regulates murine T cell activation. However, its expression and function on human T 
cells is currently unknown. We report in this study on the expression of BTLA in human T cell subsets 
as well as its regulation on virus-specific T cells during primary human CMV infection. BTLA is 
expressed on human CD4 T cells during different stages of differentiation, whereas on CD8 T cells, it 
is found on naive T cells and is progressively downregulated in memory and differentiated effector-
type cells (Serriari et al., 2010). During primary CMV infection, BTLAwas highly induced on CMV-
specific CD8 T cells immediately following their differentiation from naive cells. After control of 
CMV infection, BTLA expression went down on memory CD8 cells. Engagement of BTLA by mAbs 
blocked CD3/CD28-mediated T cell proliferation and Th1 and Th2 cytokine secretion. Finally, in vitro 
blockade of the BTLA pathway augmented, as efficient as anti–PD-1 mAbs, allogeneic as well as 
CMV-specific CD8 T cell proliferation. Thus, our results suggest that, like PD-1, BTLA provides a 
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